AVONEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AVONEX (AVONEX).
Interferon beta-1a binds to type I interferon receptors, activating the JAK-STAT signaling pathway, which leads to increased expression of anti-inflammatory cytokines (e.g., IL-10, IL-4) and downregulation of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α). It also reduces T-cell activation, inhibits matrix metalloproteinases, and decreases blood-brain barrier permeability, thereby reducing inflammatory demyelination in multiple sclerosis.
| Metabolism | Interferon beta-1a is metabolized via general protein catabolism. No specific cytochrome P450 involvement; route of elimination is primarily renal (glomerular filtration and proteolytic degradation). |
| Excretion | Renal (primarily catabolism and excretion of small peptides and amino acids). No biliary or fecal elimination reported. |
| Half-life | Terminal half-life is 10 hours (range 6–15 hours) after IM administration. Clinical context: supports weekly dosing; trough levels remain above therapeutic threshold. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Mean Vd is 0.25 L/kg, indicating distribution largely within plasma and extracellular fluid, with limited tissue penetration. |
| Bioavailability | IM bioavailability is approximately 40% relative to IV administration. |
| Onset of Action | IM: Clinical effects (reduction in relapse rate) are observed after 3–6 months of continuous therapy. |
| Duration of Action | Duration of therapeutic effect extends for one week following a single 30 mcg IM injection, consistent with weekly dosing regimen. |
| Action Class | Interferons |
| Brand Substitutes | Relibeta Injection |
30 mcg intramuscularly once weekly
| Dosage form | VIAL |
| Renal impairment | No dose adjustment required for renal impairment; drug is primarily cleared by proteolysis. |
| Liver impairment | No formal guidelines; use caution in severe hepatic impairment (Child-Pugh C) due to limited data. |
| Pediatric use | Safety and efficacy not established in patients <18 years. |
| Geriatric use | No specific dose adjustment; clinical studies did not include sufficient patients ≥65 years to determine differential response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AVONEX (AVONEX).
| Breastfeeding | It is unknown whether interferon beta-1a is excreted in human milk. The M/P ratio is not available. Due to the potential for adverse effects in the nursing infant, breastfeeding is not recommended during therapy. |
| Teratogenic Risk | Interferon beta-1a (AVONEX) is not known to be teratogenic in humans. In animal studies, no embryotoxicity or teratogenicity was observed at doses up to 100 times the human dose. However, spontaneous abortion rates may be increased. No fetal risks have been identified in any trimester, but caution is advised. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to interferon beta-1a or any component of the formulation, including human albumin or mouse serum-derived components (for intramuscular formulation).","Pregnancy (based on animal studies; limited human data; consider risk-benefit)."]
| Precautions | ["Risk of hepatic injury, including elevated hepatic enzymes and hepatitis; monitor liver function tests periodically.","May cause anaphylaxis or other allergic reactions; discontinue if severe hypersensitivity occurs.","Depression and suicidal ideation have been reported; monitor mood symptoms.","Injection site reactions, including necrosis; rotate injection sites.","Flu-like symptoms (fever, chills, myalgia) are common; premedication with analgesics/antipyretics may reduce incidence.","Cardiac effects: rare cases of congestive heart failure, cardiomyopathy, and arrhythmias; use caution in patients with pre-existing cardiac disease.","Seizures: caution in patients with seizure disorders.","Hematologic effects: may cause thrombocytopenia and pancytopenia; monitor blood counts if symptoms occur.","Thyroid dysfunction: monitor thyroid function in patients with thyroid disease."] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring |
| Monitor for clinical signs of hepatic injury (elevated liver enzymes) and myelosuppression (complete blood counts) during pregnancy. Fetal ultrasound may be considered if maternal complications arise. |
| Fertility Effects | Infertility was not observed in animal studies. Based on the drug's mechanism, no significant impact on fertility is expected, although menstrual irregularities have been reported in some women. No human data on fertility are available. |
| No specific food interactions; maintain adequate hydration to manage injection site reactions. |
| Clinical Pearls | Administer IM once weekly; rotate injection sites. Pre-medicate with acetaminophen or NSAIDs and antihistamines for flu-like symptoms. Monitor for neutralizing antibodies which may reduce efficacy. Avoid in pregnancy unless benefit outweighs risk. |
| Patient Advice | Inject exactly as prescribed, once weekly intramuscularly. · Expect flu-like symptoms after injection; use over-the-counter fever reducers. · Rotate injection sites (thigh, arm, abdomen) to minimize injection site reactions. · Store in refrigerator, do not freeze; protect from light. · Contact doctor if symptoms worsen or new symptoms appear. · Report any signs of depression or suicidal thoughts immediately. |